New hope for kids with tough cancers: SGT-53 drug trial launches
NCT ID NCT02354547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called SGT-53, given alone or with chemotherapy, in children and young adults (ages 1-21) with solid tumors that have come back or not responded to treatment. The main goals are to find safe doses and understand side effects. The study is currently on hold.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart digital program restore sleep for cancer survivors?
- AI that reads faces could spot hidden distress in cancer patients
- A smartphone program aims to ease the emotional toll of fertility loss in young cancer survivors
- Island hopping for cancer care: first study maps Survivors' journeys across six caribbean nations
- 4D MRI scans could reveal hidden clues about heart disease and cancer
- Immune cell 'Packages' injected into tumors: a new hope for advanced cancer?